In relatively small and nonrandomized subsets of patients enrolled in EMERGE/ENGAGE and CLARITY-AD, amyloid-lowering treatment was associated with reductions or slowed progression of regional tau PET signal (14,15). This evidence concerns the gene MAPT and Alzheimer disease.